Researchers have claimed to have discovered that influenza has an Achilles' heel.
The study reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus.
Senior study author Maziar Divangahi of McGill University, said drugs that specifically target PGE2 pathways have already been developed and tested in animals, so their results have excellent potential for clinical translation, not only for the treatment of influenza, but also other viral respiratory infections that interact with similar host immune pathways.
In the new study, Divangahi and his team found that mice genetically engineered to lack PGE2 showed enhanced immune responses, lower viral levels in the lungs, and better survival rates following infection with a lethal dose of the H1N1 flu virus compared with infected mice that were not genetically modified.
Similarly, mice treated with a compound that inhibits PGE2 showed enhanced antiviral immunity and survival rates following infection with a lethal dose of the flu virus compared with untreated mice.
The study has been published by journal Cell Press.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
